Celanese Corporation
CE
$0.00
+5.49%
Celanese Corporation is a global chemical and specialty materials company, operating primarily in the Basic Materials sector. It is a leading producer of acetic acid and its downstream derivatives, as well as a major manufacturer of specialty polymers used in automotive, electronics, medical, and consumer end markets. The current investor narrative is dominated by the company's volatile earnings recovery from a significant loss in Q3 2025, with recent quarterly results showing a return to profitability, driving debate around the sustainability of its margin improvement and cash flow generation amidst cyclical demand pressures in its key industrial end markets.…
CE
Celanese Corporation
$0.00
Investment Opinion: Should I buy CE Today?
Rating & Thesis: Hold. Celanese presents a high-risk, high-potential-reward deep-value situation, but the current evidence of sustained fundamental recovery is insufficient to warrant a Buy rating. The mixed analyst sentiment, with ratings ranging from 'Neutral' to 'Overweight' and an average EPS target of $11.95, reflects this uncertainty.
Supporting Evidence: The primary valuation metric, a trailing PS ratio of 0.49, is at a deep discount to both industry peers and its own history, suggesting significant embedded pessimism. The forward P/E of 8.07 is low, implying the market doubts the analyst consensus for a sharp EPS recovery to $11.95. While Q4 showed a return to profitability with an 8.0% operating margin, revenue remains in a downtrend, declining 7% YoY. The strong TTM FCF of $803M is a positive, but it is overshadowed by the highly leveraged balance sheet (D/E of 3.19) and negative shareholder returns (ROE of -28.8%).
Risks & Conditions: The two biggest risks are 1) a failure to stabilize revenues, and 2) a return to significant quarterly losses that jeopardize debt servicing. This Hold would upgrade to a Buy if the company demonstrates two consecutive quarters of sequential revenue growth and sustains an operating margin above 10%, confirming the recovery. It would downgrade to a Sell if revenue declines accelerate beyond 10% YoY or if net income turns negative again. Relative to its history and the challenged fundamentals, the stock is fairly valued for the elevated risk it carries, but it is undervalued if the earnings recovery materializes as analysts project.
Sign up to view all
CE 12-Month Price Forecast
The assessment is neutral with medium confidence. The stock is a classic 'show me' story trading at crisis-level valuations. The bull case relies on a successful cyclical recovery that is not yet visible in the revenue trend, while the bear case is supported by recent history of massive losses and high leverage. The base case of a grinding, volatile recovery is most probable. The stance would turn bullish on evidence of sustained sequential revenue growth and margin expansion for two quarters. It would turn bearish on a confirmation of renewed revenue decline or a return to quarterly losses.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Celanese Corporation's 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
5 analysts
Implied Upside
—
vs. current price
Analyst Count
5
covering this stock
Price Range
$0 - $0
Analyst target range
Analyst coverage for Celanese is limited, with only 5 analysts providing estimates, indicating it may be a less-followed large-cap stock. The consensus sentiment appears mixed-to-neutral, with recent institutional ratings from firms like UBS and JP Morgan at 'Neutral', Wells Fargo at 'Overweight', and Citigroup at 'Buy'. The average revenue estimate for the next period is $8.83 billion, with a wide range from $8.32 billion to $9.57 billion, reflecting uncertainty in end-market demand. The average EPS estimate is $11.95, with a low of $11.05 and a high of $13.25. The wide target range for both revenue and EPS signals high uncertainty among analysts regarding the company's near-term earnings power, likely tied to volatile input costs and demand in the chemical sector. The limited number of analysts and the divergence in revenue targets suggest that while there is institutional interest, conviction on the path forward is low, which can contribute to higher stock price volatility as new data emerges.
Bulls vs Bears: CE Investment Factors
The bull and bear cases for Celanese are starkly divided, with the bear side currently holding stronger evidence due to the company's demonstrable fundamental deterioration. The bear case is supported by concrete data: severe earnings volatility, declining revenue, high leverage, and massive underperformance. The bull case rests primarily on deep-value valuation and the potential for a cyclical recovery, which is not yet evident in the top-line trends. The single most important tension in the investment debate is whether the Q4 2025 return to modest profitability represents a sustainable inflection point or merely a temporary respite before further cyclical pressure. The resolution of this tension—specifically, the trajectory of revenue and operating margins over the next two quarters—will determine if the stock's deep discount is a value trap or a compelling opportunity.
Bullish
- Deeply Undervalued on Sales: The stock trades at a trailing PS ratio of 0.49, near the bottom of its multi-year historical range and at a significant discount to the chemical industry average, which often trades above 1.0x. This suggests the market is pricing in a worst-case scenario, offering a substantial margin of safety if the company stabilizes.
- Strong Free Cash Flow Generation: Despite earnings volatility, the company generated robust TTM free cash flow of $803 million. This provides crucial financial flexibility to service its high debt load and potentially return capital to shareholders, underpinning the balance sheet during a cyclical downturn.
- Sharp Q4 Profitability Rebound: The company swung from a massive $1.357 billion net loss in Q3 2025 to a $19 million net income in Q4 2025, with operating margin recovering to 8.0%. This dramatic sequential improvement, if sustained, signals a potential exit from the worst of its operational challenges.
- Low Forward P/E Implies Recovery: The forward P/E of 8.07, based on analyst consensus EPS of $11.95, is very low for a large-cap industrial company. This multiple prices in significant skepticism, leaving room for multiple expansion if the company meets or exceeds these recovering earnings estimates.
Bearish
- Extreme Earnings Volatility & Losses: The company's profitability is highly erratic, with a trailing net margin of -12.2% and a staggering quarterly swing from a -$1.357B loss to a $19M profit. This volatility, driven by large one-time charges in Q3 2025, makes forecasting future earnings exceptionally difficult and risky.
- High Financial Leverage: With a debt-to-equity ratio of 3.19, the company carries a highly leveraged balance sheet. This amplifies risk during downturns, as interest expense of over $200M per quarter consumes cash flow and limits financial flexibility.
- Persistent Revenue Decline: Q4 2025 revenue of $2.204B declined 7% year-over-year, continuing a volatile multi-quarter downtrend from a peak of $2.652B in Q2 2024. This indicates fundamental demand weakness in its key acetyl chain and engineered materials end markets.
- Severe Underperformance vs. Market: The stock's 1-year return of -5.96% significantly underperforms the S&P 500's 22.86% gain, a -28.8% relative strength gap. This persistent weakness reflects a loss of investor confidence and ongoing sector/company-specific headwinds.
CE Technical Analysis
The stock is in a volatile, range-bound consolidation phase after a significant rally earlier in the year. The 1-year price change is -5.96%, underperforming the S&P 500's 22.86% gain, indicating a pronounced downtrend on a relative basis. Currently trading at $53.48, the price sits at approximately 51% of its 52-week range ($35.13 to $70.70), suggesting it is in the middle of its annual band, reflecting a balance between recovery potential and lingering fundamental concerns. Recent short-term momentum is decisively negative, with the stock down 10.82% over the past month and 7.38% over the past three months, sharply diverging from the positive 22.94% return over the last six months. This recent weakness, highlighted by a relative strength of -10.74% versus the S&P 500 over one month, signals a breakdown from its earlier 2026 highs and a potential retest of lower support levels. Key technical support is at the 52-week low of $35.13, while immediate resistance is at the 52-week high of $70.70. A break below the recent lows near $49 could signal a test of deeper support, while a move above the $65-$70 range would require a fundamental catalyst. The stock's beta of 0.738 indicates it is about 26% less volatile than the broader market, which is notable given the significant price swings observed in the data.
Beta
0.76
0.76x market volatility
Max Drawdown
-43.0%
Largest decline past year
52-Week Range
$35-$71
Price range past year
Annual Return
-21.3%
Cumulative gain past year
| Period | CE Return | S&P 500 |
|---|---|---|
| 1m | -13.7% | -1.3% |
| 3m | -25.6% | +13.6% |
| 6m | +13.1% | +9.0% |
| 1y | -21.3% | +19.1% |
| ytd | +13.1% | +9.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CE Fundamental Analysis
Revenue trends show a challenging environment, with the most recent quarterly revenue of $2.204 billion representing a 7% year-over-year decline. The multi-quarter trend reveals high volatility, with revenue swinging from $2.371B in Q4 2024 to $2.652B in Q2 2024, then down to $2.204B in Q4 2025. The Engineered Materials segment generated $1.277 billion in the latest period, slightly larger than the Acetyl Chain segment at $940 million, indicating both core businesses are facing pressure. Profitability is highly inconsistent, as evidenced by a trailing net margin of -12.2% and a gross margin of 18.8%. The company swung from a massive net loss of -$1.357 billion in Q3 2025 to a net income of $19 million in Q4 2025, with an operating margin of 8.0% in that most recent quarter. This erratic pattern, moving from deeply negative EBITDA of -$982 million in Q3 to positive $411 million in Q4, underscores significant one-time charges or operational volatility. The balance sheet carries substantial leverage, with a debt-to-equity ratio of 3.19, indicating a highly leveraged capital structure. However, the company generated robust free cash flow of $803 million on a TTM basis, providing some cushion. The current ratio of 1.55 suggests adequate short-term liquidity, but the negative Return on Equity of -28.8% highlights severe pressure on shareholder returns from the recent losses.
Quarterly Revenue
$2.2B
2025-12
Revenue YoY Growth
-0.07%
YoY Comparison
Gross Margin
+0.17%
Latest Quarter
Free Cash Flow
$803000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CE Overvalued?
Given the negative trailing net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 0.49, while the forward PS, implied by the market cap of $4.63B and estimated revenue of $8.83B, is approximately 0.52, suggesting the market expects roughly stable sales. This sales multiple is at a significant discount to the industry, as chemical companies often trade above 1.0x sales, indicating the market is pricing in substantial profitability and growth concerns. The stock also trades at a forward P/E of 8.07, which appears low but is based on a projected sharp earnings recovery. Historically, the stock's own valuation has compressed dramatically; its PS ratio was as high as 9.46 in early 2021 and has fluctuated between 0.49 and 7.15 over the provided historical data. The current PS of 0.49 is near the very bottom of its multi-year historical range, suggesting the market is pricing in a pessimistic scenario of prolonged earnings pressure or balance sheet stress, potentially offering a deep-value opportunity if fundamentals stabilize.
PE
-4.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -74x~61x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
55.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Celanese faces significant financial risk from its highly leveraged balance sheet, with a debt-to-equity ratio of 3.19. This debt burden is compounded by extreme earnings volatility, as evidenced by the swing from a -$1.357B net loss to a $19M profit in consecutive quarters, driven by large, non-recurring charges. While TTM free cash flow of $803M provides a cushion, the company's negative ROE of -28.8% and gross margin pressure at 18.8% indicate underlying profitability is severely challenged, raising questions about its ability to consistently service debt and fund operations if the recovery stalls.
Market & Competitive Risks: The stock's valuation, while cheap on a PS basis at 0.49x, carries the risk of remaining 'cheap for a reason' if the cyclical downturn in its key industrial end markets (automotive, electronics, construction) persists. The company's beta of 0.738 suggests it is less volatile than the market, but its own price action shows high volatility, indicating idiosyncratic, company-specific risks dominate. A key risk is valuation compression if the projected earnings recovery (forward P/E of 8.07) fails to materialize, potentially leading to further multiple derating. Competitive pressures and input cost volatility in the chemical sector add further uncertainty.
Worst-Case Scenario: The worst-case scenario involves a relapse into significant quarterly losses, similar to Q3 2025, triggered by a deeper-than-expected industrial recession that crushes demand and margins. This could strain liquidity despite current FCF, lead to credit rating downgrades on its high debt, and force asset sales or equity dilution. In this adverse scenario, the stock could retest its 52-week low of $35.13, representing a downside of approximately -34% from the current price of $53.48. The historical max drawdown of -43% provides a precedent for such severe declines during periods of operational stress.
FAQ
The key risks are, in order of severity: 1) Financial Risk: High debt-to-equity (3.19) amplifies downside during downturns, and extreme earnings volatility (e.g., a $1.357B quarterly loss) threatens liquidity. 2) Operational Risk: Revenue is declining (-7% YoY) and gross margins are weak (18.8%), indicating poor demand and pricing power in its core markets. 3) Market Risk: The stock has severely underperformed the S&P 500 by -28.8% over the past year, reflecting a loss of investor confidence that may persist. 4) Recovery Execution Risk: The company's ability to meet analyst EPS estimates of $11.95 is highly uncertain given its recent track record.
The 12-month forecast is highly bifurcated, with a base case target range of $55-$70 (55% probability), a bull case of $70-$85 (25% probability), and a bear case of $35-$50 (20% probability). The base case, which is most likely, assumes the company meets average analyst EPS estimates of ~$11.95 amid a slow, uneven recovery in its end markets. The bull case requires a sustained operational turnaround beating estimates, while the bear case involves a relapse into losses and a retest of the 52-week low of $35.13. The wide range reflects the extreme uncertainty stemming from the company's volatile quarterly results.
CE appears deeply undervalued based on traditional sales multiples but fairly valued given its severe fundamental challenges. Its trailing Price-to-Sales (PS) ratio of 0.49 is near the bottom of its multi-year historical range and a significant discount to the chemical industry, which often trades above 1.0x sales. Its forward P/E of 8.07 is also low. However, this discount reflects real risks: negative trailing net margin (-12.2%), high leverage, and declining revenue. The valuation implies the market expects either a prolonged period of depressed earnings or further deterioration. It is undervalued only if the company can stabilize and grow profits as analysts project.
CE is a high-risk, high-potential-reward stock that is only a good buy for specific investors. For deep-value, contrarian investors willing to tolerate significant volatility and who have a conviction in a cyclical industrial recovery, the current valuation (PS of 0.49, forward P/E of 8.07) may be attractive. The average analyst EPS target of $11.95 implies substantial upside if achieved. However, for most investors, it is not a good buy due to its extreme earnings volatility, high debt (D/E 3.19), and persistent revenue decline of -7% YoY. The key risk is that the recent return to profitability is not sustained.
CE is unsuitable for short-term trading due to its high volatility and sensitivity to quarterly earnings surprises, which can be extreme (as seen in Q3 2025). Its low beta of 0.738 is misleading given its own price swings. It is only suitable for long-term, patient investors with a minimum 2-3 year horizon who are betting on a full cyclical recovery in the chemical industry and a successful company-specific turnaround. The investment thesis is based on valuation normalization over years, not near-term catalysts. The negligible dividend yield (0.28%) also means it offers no income support for short-term holders.